Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dyax, Defiante extend agreement to commercialize Kalbitor
In addition to receiving an upfront payment of $1m, which includes $500,000 in cash and $500,000 in equity shares at a 50% premium investment, Dyax is eligible for
In addition to receiving an upfront payment of $1m, which includes $500,000 in cash and $500,000 in equity shares at a 50% premium investment, Dyax is eligible for
The analysed drugs include Pfizer’s Celebrex, Merck’s Vioxx, Novartis’s Prexige, the experimental etoricoxib, ibuprofen, and diclofenac. Naproxen and Ibuprofen (sold as Advil) were found to be the least
Amgen plans to simultaneously develop three oncology drugs, the most advanced of them being Motesanib, which is being developed in collaboration with the Tokyo-based Takeda Pharmaceutical. Referring to
The milestone payment will also be used to start a Phase 1 clinical trial of a HuCAL-derived, fully human antibody to treat inflammatory diseases. MorphoSys chief scientific officer
Cravit IV, administered once daily, is classified as a respiratory quinolone suited to treat respiratory tract infections. Daiichi said that 100mg Cravit tablets were approved in Japan for
The company expects to initiate a Phase 1/2 clinical trial to investigate the safety and efficacy of the drug, in 2011. ISV-101 combines a low dose of the
Amarin has two final-stage human tests of its advanced experimental cholesterol drug AMR101. Bloomberg.com has quoted San Francisco-based Wedbush Securities analyst Duane Nash as saying that the cholesterol
HGS is set to start selling Benlysta along with its partner, London-based GlaxoSmithKline, if the USFDA clears the medicine by 10 March, reported Bloomberg.com. Benlysta prevents the production
SciClone Pharma will recruit around 160 patients who are receiving standard chemoradiation therapy for treatment head and neck cancers. In the trial, the company expects to evaluate three
The results showed improvement in the primary end point, which was defined as a reduction in facial erythema, over an eight hour period in patients with erythematotelangiectatic rosacea